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In humans, cryoglobulinemia can be responsible for a membranoproliferative glomerulonephritis (MPGN), which is characterized by the formation and/or deposition of immunoglobulins (Igs) and complement in the glomeruli, followed by an influx of inflammatory cells \[[@B1], [@B2], [@B3]\]. However, the mechanisms inducing the glomerular inflammation are not fully understood. Complement is well known to mediate the processing of immune complexes \[[@B4]\]. Since the early studies to investigate complement activation by immune complexes in experimental nephrotoxic nephritis, the complement system has been considered to play an important proinflammatory role in the glomerulus \[[@B5], [@B6]\]. In cryoglobulinemia, however, there is no clear evidence that complement activation is central in mediating tissue damage by immune deposits. Results have been obtained in mice by Trendelenburg et al. \[[@B7]\], who analyzed the role of complement in the pathogenesis of initial glomerular inflammation induced by murine 6--19 IgG3 monoclonal cryoglobulins. They used two different strains of mice developing either type I or II cryoglobulinemia. Their results indicated that complement C5 has a predominant role in neutrophil recruitment as C5-deficient mice had significantly reduced glomerular infiltration by polymorphonuclear neutrophils \[[@B7]\]. This is of particular interest, as the monoclonal complement C5-blocking antibody eculizumab could offer a promising therapeutic option for patients with cryoglobulin-induced glomerulonephritis.

Cryoglobulinemia is a rare disease and is characterized by Igs that precipitate in the cold. Depending on the clonality of the precipitating Igs, three types of cryoglobulinemia can be distinguished \[[@B8]\]. Type I cryoglobulinemia consists of a single monoclonal cryoprecipitable Ig, whereas type II and III cryoglobulins are mixed, i.e. composed of monoclonal (type II) and polyclonal (type III) antibodies with rheumatoid factor activity against other Igs. Mixed cryoglobulinemia may be associated with numerous infectious and immunological diseases as well as lymphatic malignancies. In particular, mixed cryoglobulinemia type II is strongly associated with chronic hepatitis C, and nowadays rarely appears as an isolated disease, i.e. the so-called essential cryoglobulinemia \[[@B9]\]. Clinically, cryoglobulinemia manifests itself with symptoms like weakness and arthralgias and variable cutaneous and visceral organ involvement \[[@B9], [@B10]\]. Overall, the prognosis is dependent on the underlying disease and affected organs. It is poorer in patients with renal involvement, liver failure, lymphoproliferative disease and malignancies \[[@B9]\]. The treatment of cryoglobulinemia is challenging. Steroids suppress inflammation with success in some patients, but additional plasmapheresis to remove circulating cryoglobulins and immunosuppressive treatment to inhibit the formation of new cryoglobulins are often necessary \[[@B11], [@B12], [@B13]\]. All of these therapies are characterized by serious side effects.

Eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, Conn., USA) is a monoclonal antibody that targets complement C5 and prevents the cytolytic and proinflammatory effects of complement activation \[[@B14]\]. Eculizumab is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria. It effectively reduces intravascular hemolysis, thereby improving anemia and quality of life and decreases transfusion requirements \[[@B15], [@B16]\]. Since the initial validation of inhibition of a complement component as a therapeutic target, the field for the use of eculizumab has been expanded \[[@B17]\]. Recently, eculizumab has been approved from the FDA for the treatment of patients with atypical hemolytic uremic syndrome, in whom the control of complement activation is insufficient. Furthermore, eculizumab has been successfully used preemptive prior to kidney transplantation \[[@B18], [@B19]\] or postoperatively to prevent disease recurrence in the allograft \[[@B20], [@B21], [@B22]\] in several cases with complement disorder-associated atypical hemolytic uremic syndrome.

Here, we report on an exceptional case of mixed essential cryoglobulinemia with severe glomerulonephritis characterized by a prominent infiltration of the glomeruli by neutrophils. A 1-patient clinical trial of eculizumab was attempted to investigate whether complement inhibition would be sufficient to inhibit this relapsing glomerulonephritis. The initial partial response was, however, not sustained, and the patient returned to intermittent plasmapheresis.

Case Report and Therapeutical Trial {#sec1_2}
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A 55-year-old woman was diagnosed with a mixed type II cryoglobulinemia (monoclonal IgM-kappa and polyclonal IgG) and immune complex-mediated glomerulonephritis in May 2006. She developed an acute nephritic syndrome with pathological urinary sediment (i.e. dysmorphic erythrocytes, cellular casts and leucocytes), high proteinuria (7 g/day), arterial hypertension, volume overload and moderate renal function impairment, which got worse over time. Further, she suffered from weakness and arthralgias, but other organ manifestations besides the kidney were not present. The first renal biopsy showed endocapillary hypercellularity with infiltration of mononuclear cells, an unusual high number of neutrophils, and subendothelial immune deposits, which were positive for IgM as well as complement C3 and C5b-9, resembling acute poststreptococcal glomerulonephritis; however, classical humps were missing (fig. [1](#F1){ref-type="fig"}). Comprehensive blood examinations revealed cryoglobulins (0.6 g/l), a monoclonal IgM (2 g/l), hypogammaglobulinemia (\<5 g/l), and low complement C3 and C4 levels. Extensive screening for an infectious disease (i.e. serological testing and PCR for HIV, HCV, HBV, CMV and EBV) and malignancy (bone marrow biopsy, computed tomography of the chest and abdominal organs) was negative. Further, autoantibodies were negative (ANA, ANCA, anti-DNA, antiphospholipid antibodies) except for rheumatoid factor, with a titer \>1/10,000. A second renal biopsy 1 year later showed early stage MPGN with a still high number of neutrophils, which was interpreted as a progression of disease.

The patient was unresponsive to high-dose steroids and subsequently received cyclophosphamide pulse therapy, mycophenolat mofetil and two courses of the monoclonal anti-CD20 antibody rituximab. These immunosuppressive therapies all failed to get the cryoglobulin-induced glomerulonephritis under control. On October 2006, once to twice weekly plasmapheresis was started with success. However, plasmapheresis was complicated by two catheter-related blood stream infections. In addition, she suffered from headache and complained about unpleasant diaphoresis during the procedures. At the request of the patient, plasmapheresis was interrupted several times with prompt disease relapses manifested by an increase in serum creatinine and proteinuria, and reinstitution of intensive plasmapheresis. Thus, we designed a protocol to test whether eculizumab could replace plasmapheresis at the time of a relapse. The protocol was approved by the local ethical committee, and informed consent was provided in accordance with the Declaration of Helsinki. Criteria for treatment success were: (i) prevention of progression as determined by maintenance or improvement in renal function, (ii) reduction of proteinuria, and (iii) no appearance of new extrarenal disease manifestations.

In June 2011, the study was started after the last series of plasma exchange, with a continuous surveillance of renal function and clinical signs of relapse. As expected from previous intervals between plasmapheresis series, it took 3 weeks until relapse. Eculizumab was dosed at 900 mg intravenously every 7 days for 4 weeks, at 1,200 mg 7 days later, and another dose of 1,200 mg 14 days later. At that time of initiating eculizumab therapy, serum creatinine level was 340 μmol/l (eGFR 13 ml/min), proteinuria was 8 g/day and the patient still had nephritic urinary sediment. The patient had been vaccinated against *Neisseria meningitis* 14 days prior to receive the first dose of eculizumab. Fig. [2](#F2){ref-type="fig"} shows the clinical course and renal function (i.e. serum creatinine and proteinuria), before and after initiating eculizumab. Blood samples were drawn to control blood concentrations of eculizumab and blockage of the complement system during the treatment. Complement activity was shown to be blocked using a hemolytic assay (CH50) and by the drop to background of the high levels of soluble C5b-9 (MicroVue® Complement SC5b-9 Plus; Quidel Corporation, San Diego, Calif., USA) (data not shown). As expected, complement C3 and C4 levels remained low during eculizumab therapy. The eculizumab infusions were well tolerated and the patient reported an improvement in her well-being. Nevertheless, without plasmapheresis the blockage of the terminal complement was not sufficient to control the disease. Proteinuria remained at high levels of 6--8 g/day, hematuria persisted and renal function remained stable for some weeks before deteriorating. After 7 weeks of therapy, the patient was urgently admitted to hospital because of fluid overload. Plasmapheresis was restarted and renal function returned almost to baseline level (fig. [2](#F2){ref-type="fig"}).
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To our knowledge, this is the first report of a clinical trial to investigate the monoclonal complement inhibitor eculizumab in a patient with mixed cryoglobulinemia and severe glomerulonephritis. The unique features of the cryoglobulinemic MPGN in this patient were the resistance to treatments such as steroids, cyclophosphamide and rituximab, the presence of high numbers of neutrophils in two renal biopsies taken at 1-year interval (on both occasions at the time of a severe relapse), and the prompt response to plasmapheresis. All these features suggested that complement was a major player in the disease process: indeed complement was activated and deposited in the glomeruli, and complement factor C5a is known to be a highly active chemotactic agent for neutrophils. In addition, recently macrophages have been shown to be central to the nephritis in a model of murine cryoglobulinemic MPGN \[[@B3]\].

The improvement felt by the patient and the stabilization of the creatinine level after initiation of eculizumab suggested that complement might be involved in the inflammation and tissue damage induced by cryoglobulins. However, it became evident after 7 weeks that there was no improvement, rather a slow deterioration of renal function with ongoing signs of active nephritis in the urinary sediment. Thus, eculizumab therapy was stopped. Evidently complement blockade at the C5 level alone was insufficient. This observation does, however, not exclude a role for complement in cryoglobulin-induced glomerulonephritis. For instance, we do not know whether complement blockade would prevent a relapse, i.e. whether complement might induce a cascade of inflammatory events, which then become independent of continuous complement activation. Further, one can argue that the blockage of C5 by eculizumab plays a central role to prevent the chemotactic function of C5a for the recruitment of neutrophils. Once they have invaded the glomerulus where the inflammatory processes take place, they act independently of complement C5a, which has no proinflammatory effects. This would be an argument for a prophylactic and sustained use of eculizumab in patients with cryoglobulinemia when the disease is in remission and against its use as a salvage therapy in disease relapse, to induce a more prolonged remission or reduce the frequency of relapses. This argumentation is supported by the mouse model reported by Trendelenburg et al. \[[@B7]\], where the C5-deficient mice had impressively less influx of neutrophils, as their experimental model of cryoglobulin-induced glomerulonephritis rather resembles a model of preemptive blockage of C5a to prevent glomerular inflammation just at the beginning and not when the inflammatory process is fully developed as it is in case of a relapse. In addition, eculizumab will not prevent the deposition of C3 fragments and release of C3a, which by themselves might interact with complement receptors on mesangial cells, macrophages/monocytes and neutrophils and activate these cells.

Usually, the development of clinical therapy protocols relies on evidence-based guidelines that mainly focus on randomized, controlled trials; however, for rare diseases, such as in the present case of essential cyoglobulinemia, treatment options rely on similarities to other diseases and the understanding of the pathological process on experimental data obtained in animal models. Since human data of cryoglobulinemia are scarce, the present 1-patient trial report demonstrating the response to eculizumab--whether considered partially positive or negative -- might be of use for the medical community.
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![Renal biopsy findings in a patient with a cryoglobulin-induced immune complex glomerulonephritis. **A** Overview showing endocapillary glomerulonephritis with impressive hypercellularity. **B** Section of a glomerulus with mononuclear cells and polymorphonuclear neutrophils (indicated by arrows) in the glomerular convolutes. Immune complex-mediated glomerulonephritis positive for IgM (**C**) and complement C3 (**D**) by immunofluorescence staining.](cru-0002-0038-g01){#F1}
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